Alkermes plc (ALKS) is a publicly traded company in the Healthcare — Drug Manufacturers - Specialty & Generic industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Price
| Price | $46.07 |
| Market Cap | $7.7B |
| Exchange | NASDAQ |
| Country | IE |
Valuation Ratios
| P/E Ratio | 112.07 |
| Price / Book | 4.16 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 84.56% |
| Operating Margin | 7.03% |
| Net Margin | 3.97% |
Financial Health
| Debt / Equity | 0.87 |
| Current Ratio | 2.30 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ALKS | Alkermes plc | $7.7B | 112.07 | 4.16 | |
| TAK | Takeda Pharmaceutical Company Limited | $59.4B | 51.19 | 1.21 | 2.6% |
| TEVA | Teva Pharmaceutical Industries Limited | $45.0B | 61.47 | 5.82 | 17.8% |
| HLN | Haleon plc | $40.5B | 18.64 | 1.84 | 9.9% |
| 0M3Q.L | Zoetis Inc. | $35.4B | |||
| ZTS | Zoetis Inc. | $30.6B | 11.99 | 9.67 | 69.3% |
| HLN.L | Haleon plc | $29.4B | 18.73 | 1.85 | 9.9% |
| 0SAN.L | Sandoz Group AG | $28.3B | 52.81 | 3.84 | 7.0% |
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ALKS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks